Erste Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $636K | Buy |
17,421
+2,411
| +16% | +$88.1K | 0.01% | 588 |
|
|
2025
Q1 | $568K | Hold |
15,010
| – | – | 0.01% | 420 |
|
|
2024
Q4 | $652K | Hold |
15,010
| – | – | 0.01% | 419 |
|
|
2024
Q3 | $817K | Hold |
15,010
| – | – | 0.01% | 397 |
|
|
2024
Q2 | $622K | Hold |
15,010
| – | – | 0.01% | 405 |
|
|
2024
Q1 | $703K | Hold |
15,010
| – | – | 0.01% | 398 |
|
|
2023
Q4 | $725K | Hold |
15,010
| – | – | 0.01% | 397 |
|
|
2023
Q3 | $528K | Hold |
15,010
| – | – | 0.01% | 402 |
|
|
2023
Q2 | $700K | Hold |
15,010
| – | – | 0.01% | 388 |
|
|
2023
Q1 | $580K | Hold |
15,010
| – | – | 0.01% | 415 |
|
|
2022
Q4 | $678K | Hold |
15,010
| – | – | 0.01% | 402 |
|
|
2022
Q3 | $609K | Hold |
15,010
| – | – | 0.01% | 399 |
|
|
2022
Q2 | $904K | Hold |
15,010
| – | – | 0.02% | 367 |
|
|
2022
Q1 | $1.07M | Sell |
15,010
-2,200
| -13% | -$157K | 0.02% | 347 |
|
|
2021
Q4 | $1.42M | Hold |
17,210
| – | – | 0.03% | 325 |
|
|
2021
Q3 | $1.48M | Hold |
17,210
| – | – | 0.03% | 303 |
|
|
2021
Q2 | $1.66M | Hold |
17,210
| – | – | 0.03% | 305 |
|
|
2021
Q1 | $1.93M | Hold |
17,210
| – | – | 0.05% | 272 |
|
|
2020
Q4 | $2.54M | Sell |
17,210
-1,200
| -7% | -$177K | 0.07% | 241 |
|
|
2020
Q3 | $1.57M | Sell |
18,410
-76,900
| -81% | -$6.54M | 0.05% | 271 |
|
|
2020
Q2 | $7.25M | Hold |
95,310
| – | – | 0.29% | 108 |
|
|
2020
Q1 | $4.23M | Hold |
95,310
| – | – | 0.25% | 115 |
|
|
2019
Q4 | $4.1M | Hold |
95,310
| – | – | 0.18% | 129 |
|
|
2019
Q3 | $4.06M | Hold |
95,310
| – | – | 0.22% | 117 |
|
|
2019
Q2 | $5.99M | Hold |
95,310
| – | – | 0.32% | 84 |
|
|
2019
Q1 | $6.56M | Buy |
95,310
+7,600
| +9% | +$523K | 0.37% | 67 |
|
|
2018
Q4 | $3.68M | Buy |
+87,710
| New | +$3.68M | 0.25% | 107 |
|